BFRI ▼ -5.2% - Biofrontera Inc. $BFRI BFRIW - Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma Biofrontera shares fell 5.2% despite the company announcing FDA approval of Ameluz® Red Light PDT for treating superficial basal cell carcinoma, a actinic keratosis treatment that expands the company's dermatology portfolio. The decline suggests investors may have viewed the approval as already priced in or had expected a broader indication or stronger commercial potential from the clearance. 14-SEP-2026 09:26 AM ET